# Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

> **NCT00166322** · NA · COMPLETED · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 35 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **PROCEDURE:** IBZM-SPECT (bolus and constant infusion paradigm)

## Key facts

- **NCT ID:** NCT00166322
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2008-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00166322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00166322, "Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00166322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*